1 / 14

Aarkstore Market Research Report - Frontier Pharma Parkinson

The “Parkinsons disease” (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. For More Details: http://goo.gl/a4BN91

addyparker2350
Download Presentation

Aarkstore Market Research Report - Frontier Pharma Parkinson

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aarkstore Market Research Report - Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation To buy this Report Visit http://www.aarkstore.com

  2. Discounted Market Research Reports available on Aarkstore.com Offer valid till 28th February, 2015 • For more inquiries, contact at +91 9987295242 / 022-27564953 • Email: enquiry@aarkstore.com To buy this Report Visit http://www.aarkstore.com

  3. Aarkstore Market Research Report - Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation To buy this Report Visit http://www.aarkstore.com

  4. Summary Large Degree of Innovation in Parkinsons Disease Pipeline The Parkinsons disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes. This diversity is partially due to the presence of 90 first-in-class products, which accounts for 37% of the overall pipeline therapies that disclosed their target. In an industry, market and development landscape that favors first-in-class over non-first-in-class development in many ways, such as through faster approval or greater revenue, this finding has strategic implications for a wide array of market participants, both large and small. Despite their historically high attrition rate, first-in-class therapies that reach the market have the potential to transform and improve the PD treatment landscape.

  5. Summary Alignment of First-in-Class Molecular Target with Disease Processes and Genetics PD is a complex and multifaceted disease with a complex interplay between different pathological processes. Enormous research efforts and significant technological advances have furthered knowledge of the neuroanatomy of the basal ganglia and of the fundamental processes underlying neurodegeneration, helped by the ongoing identification of susceptibility genes and causative genes in familial PD. Although the exact mechanisms that initiate onset remain unclear, these insights have been translated into the pool of novel therapeutic targets, which may potentially become disease-modifying therapies by aligning to the disease processes and some genetic determinants of PD.

  6. Summary First-in-Class Products in Licensing and Co-development Deals Strategic consolidation is relatively uncommon in the PD market. Concerning first-in-class specifically, only nine first-in-class products that are currently in development have been involved in licensing or co-development deals since 2006. Despite the low sample size, it is clear that the first-in-class PD products offer an attractive investment prospect as they command much higher deal values and, on average, deals occur earlier in development compared to non-first-in-class counterparts. Both trends were substantiated by industry-wide data that showed that, particularly in Phase I, first-in-class products would attract larger mean and median total deal values. The data highlight that the first-in-class deals landscape is different and indicates a greater chance of becoming much more lucrative than the deals landscape for addition-to-class or advance-in-class therapies.

  7. Scope The report analyzes innovation in PD in the context of the overall pipeline and current market landscape. It also analyzes the deals landscape surrounding first-in-class products and pinpoints in-licensing opportunities.The report includes - - A brief introduction to PD, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms- Coverage of the changing molecular target landscape and particular points of innovation in the pipeline- A comprehensive review of the pipeline for first-in-class therapies, analyzed by stage of development, molecule type and molecular target- Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets- Industry-wide analysis of first-in-class deals compared to non-first-in-class deals- An assessment of the licensing and co-development deal landscape for PD therapies and benchmarking of deals comparing first-in-class and non-first-in-class-products

  8. Reasons To Buy The report will enable business development and enable marketing executives to strategize their product launches by allowing them to - - Understand the focal shifts in molecular targets in the PD pipeline- Understand the distribution of pipeline programs by phase of development, molecule type and molecular target- Access a scientific and clinical analysis of first-in-class developmental programs for PD, benchmarked against non-first-in-class targets- Assess the valuations of licensed and co-developed PD treatments- Access a list of the first-in-class therapies potentially open to deal-making opportunities To know more about this report click here: http://www.aarkstore.com/healthcare/89790/frontier-pharma-parkinsons-disease-identifying-and-commercializing-first-in-class-innovation

  9. Table of Contents Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation Executive Summary The Case for Innovation Clinical and Commercial Landscape Assessment of Pipeline Product Innovation

  10. Price Chart Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation Product Price : Click Here To View OR Purchase Report:

  11. Related Market Research Report • Traffic Safety Market in India 2015-2019 • Blood Coagulation Analyzer – Product Analysis • Global Equine Healthcare Market 2015-2019 • Epilepsy Market in the US 2015-2019 • Global Ankylosing Spondylitis Market 2015-2019

  12. Sickle-cell Anemia Therapeutics Market in the US 2015-2019 • Global High-performance Thermoplastics Market 2015-2019 • Global Anxiety Disorders Market 2015-2019 • Global Breast Imaging Market 2015-2019 • Global Cancer Biomarkers Market 2015-2019 • Healthcare Market Research Reports

  13. About Aarkstore Enterprise • Aarkstore Enterprise provides Industry and Market Analysis and Research Report with expertise and technology knowledge on business improvement and market acquisition. • Aarkstore achieved its debut pad in the year 2008 to explore, work on assignments and cater worldwide clients and business giants with business research on trends, markets and technologies. The latest set of applications guarantees active analysis and Market Research understanding for budding enterpriser and consultants to relate industry ground research.

  14. Contact Us Office Office No. - 809, 8th Floor, B-Wing, Mahaavir Icon,  Plot No.- 89 & 90, Sector-15, CBD-Belapur, Navi Mumbai – 400614,  Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit : http://www.aarkstore.com OR Mail us at : contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related